Table 1. Overview of Tregitope in vivo experiments and results.

Experimental Model	Finding	Human Disease Parallel	Current Clinical Therapy	In vivo controls	Source
OVA-specific tolerance in C57BL/6 mice	Suppression of T cell proliferation; Suppression of OVA-antibody titer	Enzyme Replacement Therapy	Immune Tolerance Induction	Influenza HA (Negative CTR) No effect; IVIG CTR similar to Tregitope	L. Cousens, A. De Groot (EpiVax)
OVA-specific tolerance in DO11.10 TCR Transgenics	Suppression of T cell proliferation; induction of antigen-specific Tregs	Enzyme Replacement Therapy	Immune Tolerance Induction	Influenza HA peptide: No effect	D.Scott, Y. Su (USUHS)
EAE prevention with Tregitope In C57Bl/6	Reduction of EAE symptoms; induction of Tregs	Multiple Sclerosis	Copaxone; Interferon β Tysabri; Campath	OVA peptide (Negative CTR) No effect; IVIG CTR similar to Tregitope	S.Khoury; W. Elyaman (Brigham)
OVA Allergy Model; Therapy with Tregitope vs. IVIG	Reduction of allergic response to OVA and airway reactivity, increase in Treg Induction	Allergy	Anti-histamines, Immune Tolerance Induction	Albumin (Negative CTR) No effect; IVIG CTR similar to Tregitope	B. Mazer, A. Massoud (McGill)
Tregitope in AAV; TNBS-induced model of inflammatory colitis	Reduction of clinical and histological severity, increased Treg infiltration in the colon	Crohn’s Disease	Azathiaprine, Anti-TNF Mabs, Steroids	Saline; No effect	V. Ferreira, S. van der Marel (UniQure)
Tregitope in AAV for Gene Transfer	Suppressed CD8+-T cell response to AAV epitope in gene transfer model	Gene Transfer	Gene Transfer Vectors currently induce CTL response	Scrambled Tregitope peptide (Negative CTR) No effect	F. Mingozzi (CHOP)
Tregitope in T1D (NOD model) with insulin peptides	Suppressed development of diabetes; effect enhanced when Tregitope co-delivered with insulin	Type I Diabetes	Insulin Therapy	PPI peptides, Tet Tox peptide (Negative CTR) No effect	L. Cousens, A. De Groot (EpiVax)